TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 21, 2012, Pages 2615-2623

  Carey, Lisa A ^a   Rugo, Hope S ^c   Marcom, P Kelly ^b   Mayer, Erica L ^d   Esteva, Francisco J ^e   Ma, Cynthia X ^g   Liu, Minetta C ^h   Storniolo, Anna Maria ⁱ   Rimawi, Mothaffar F ^f   Forero Torres, Andres ^j   Wolff, Antonio C ^k   Hobday, Timothy J ^l   Ivanova, Anastasia ^a   Chiu, Wing Keung ^a   Ferraro, Madlyn ^a   Burrows, Emily ^a   Bernard, Philip S ^m   Hoadley, Katherine A ^a   Perou, Charles M ^a   Winer, Eric P ⁿ  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; INFUSION REACTION; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TIME TO PROGRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864101306     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.5579     Document Type: Article

References (31)

1. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
2. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
3. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006 (Pubitemid 43854964)
4. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
5. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003 (Pubitemid 36842560)
6. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003 (Pubitemid 37071889)
7. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004 (Pubitemid 39100473)
8. Hoadley KA, Weigman VJ, Fan C, et al: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258, 2007
9. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
10. Prat A, Parker JS, Karginova O, et al: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68, 2010
11. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006
12. Herschkowitz JI, Simin K, Weigman VJ, et al: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76, 2007
13. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004 (Pubitemid 39095313)
14. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
15. Berger VW, Ivanova A, Knoll M: Minimizing predictability while retaining balance trough the use of less restrictive randomization procedures. Stat Med 22:3017-3028, 2003 (Pubitemid 37160602)
16. O'Shaughnessy J, Weckstein D, Vukelja S, et al: Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
17. O'Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644-3648, 2007 (Pubitemid 47372602)
18. Hoeflich KP, O'Brien C, Boyd Z, et al: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15:4649-4664, 2009
19. Mirzoeva OK, Das D, Heiser LM, et al: Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells toMEKinhibition. Cancer Res 69:565-572, 2009
20. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23, 2011
21. Andre F, Job B, Dessen P, et al: Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441-451, 2009
22. Bergamaschi A, Kim YH, Wang P, et al: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040, 2006 (Pubitemid 44435537)
23. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
24. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
25. Decatris MP, Sundar S, O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat Rev 30:53-81, 2004 (Pubitemid 38240088)
26. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
27. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
28. Gradishar W: Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 3:163-171, 2009
29. Baselga J, Gomez P, Awada A, et al: The addition of cetuximab to cisplatin increases overall response rate and progression-free survival in metastatic triple-negative breast cancer:results of a randomized phase II study (BALI-1). Presented at the 35th European Society of Medical Oncology Congress, Milan, Italy, October 8-12, 2010
30. Ellis M, Tao Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
31. Carey LA, O'Shaughnessy J, Hoadley KA, et al: Potential predictive markers of cetuximab benefit in metastatic triple negative breast cancer: An analysis of two randomized phase II trials. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009